Replimune Group (FRA:7R8) Short Percentage of Float


FRA:7R8 Replimune Group Inc FRA:7R8
32 GF Score
Price €9.22
! 4 Warning Signs
View Full Analysis

What is Replimune Group Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:7R8 vs AVTX, KURA, SANA: Short Percentage of Float Comparison

For the Biotechnology subindustry, Replimune Group's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Replimune Group's Short Percentage of Float falls into.


FRA:7R8
32GF Score
Replimune Group Inc FRA:7R8
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Replimune Group Business Description

Other Exchanges REPL:USA
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score

Get the complete analysis for FRA:7R8

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.22
Price